Assessment of Clinical Experience of Triple Drug Fixed-dose Combination of Glimepiride, Metformin and Voglibose in the Management of Type 2 Diabetes Mellitus: A Retrospective Study
Introduction: Poor adherence of patients to the polypharmacy approach is a crucial challenge in the management of Type 2 Diabetes Mellitus (T2DM) and use of triple Fixed-Dose Combination (FDC) of metformin, glimepiride, and voglibose is effective in achieving glycaemic control and would aid in i...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
JCDR Research and Publications Private Limited
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/b03724fe5fce48c3a5a863774cd33c93 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Introduction: Poor adherence of patients to the polypharmacy
approach is a crucial challenge in the management of Type 2
Diabetes Mellitus (T2DM) and use of triple Fixed-Dose Combination
(FDC) of metformin, glimepiride, and voglibose is effective in
achieving glycaemic control and would aid in improved drug
adherence.
Aim: To analyse clinical profile and treatment patterns of FDC
of glimepiride, metformin, and voglibose with or without other
antidiabetic therapy in patients with T2DM.
Materials and Methods: A retrospective, observational, multicentric study conducted during August 2019 to March 2020.
Included patients of either sex, ≥18 years of age with T2DM
and who had received treatment with FDC of glimepiride,
metformin, and voglibose of varying strengths with or without
other antidiabetic therapy. Data extracted from medical records
included demographic characteristics, duration of disease, comorbidities, concomitant medications and dosage pattern. Data
were analysed using Chi-square test and Mann-Whitney U test.
Results: A total of 2650 patients with T2DM were included,
of which 1689 (63.7%) were males. The mean (standard
deviation {SD}) age was 54.2 (11.4) years. The average Body
Mass Index (BMI) was 27.2 (4.3) kg/m2
and hypertension 1656
(62.5%) and dyslipidaemia 1109 (41.9%) were the most common
co-morbidities. Dipeptidyl peptidase-4 inhibitors 908 (34.3%)
and antihypertensives 1601 (60.4%) were the most common
concomitant diabetic and non diabetic medications received,
respectively. Glimepiride (2 mg)+metformin (500 mg)+voglibose
(0.2 mg) FDC twice-a-day 878 (33.1%) was a common triple
FDC. A total of 2449 (92.4%) patients were compliant and
2585 (97.9%) achieved glycaemic goal with triple FDC treatment.
During the therapy, the majority of patients had decreased
weight 1106 (67.2%). The mean Haemoglobin A1c (HbA1c)
levels significantly decreased post-treatment (mean change
1.45%; p-value <0.001). Family history of diabetes mellitus,
obesity, sedentary lifestyle were the most common risk factors
and smoking being prevalent in males.
Conclusion: Overall results demonstrate that triple FDC of
glimepiride, metformin, and voglibose was effective in reducing
HbA1c and weight and was well tolerated. Also, it improves
compliance in Indian patients with T2DM. |
|---|